再発性卵巣上皮癌または原発性腹膜癌患者の治療におけるセツキシマブとカルボプラチン

基本情報

NCT ID

NCT00086892

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

-

治験依頼者名

GOG Foundation

概要

RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurrent ovarian epithelial cancer or primary peritoneal cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)